首页 | 本学科首页   官方微博 | 高级检索  
     

盐酸多奈哌齐胶囊及片剂的人体生物等效性研究盐酸多奈哌齐胶囊及片剂的人体生物等效性研究
引用本文:郝歆愚,丁黎,李丽敏,卞晓洁,张胜强. 盐酸多奈哌齐胶囊及片剂的人体生物等效性研究盐酸多奈哌齐胶囊及片剂的人体生物等效性研究[J]. 药学学报, 2003, 38(5): 392-394
作者姓名:郝歆愚  丁黎  李丽敏  卞晓洁  张胜强
作者单位:1. 中国药科大学,药物分析教研室,江苏,南京,210009
2. 南京医科大学,基础医学院临床药理研究所,江苏,南京,210029
摘    要:目的建立人血浆中盐酸多奈哌齐的HPLC-MS (quadrupole)测定方法,研究盐酸多奈哌齐在正常人体内的药代动力学行为,评价其两种制剂的生物等效性。方法人体实验采用双交叉设计,20名健康受试者交叉口服国产盐酸多奈哌齐胶囊和进口片剂,服药后0.5~192 h内间隔取血。血样加入内标(盐酸非洛普)经预处理后用HPLC-MS(quadrupole)法测定,检测离子为m/z 380(多奈哌齐)、m/z 344(内标),裂解电压为120 V。计算主要药动学参数,并以片剂为参比制剂,估算国产胶囊的相对生物利用度,判断生物等效性。结果国产及进口盐酸多奈哌齐制剂的生物半衰期分别为(63±10) h和(57±9) h,达峰时间分别为(3.3±0.4) h和(3.4±1.0) h,峰浓度分别为(8.5±0.4) μg·L-1和(8.1±1.0) μg·L-1。以进口制剂为对照,用AUC0-192计算的国产胶囊相对生物利用度为102%±11%。结论本实验建立的分析方法灵敏、准确、简便,统计学结果表明两种制剂生物等效。

关 键 词:多奈哌齐  药代动力学  生物等效性  高效液相色谱-质谱联用
收稿时间:2002-06-03

Bioequivalence of donepezil capsule and tablet in human
HAO Xin-yu,DING Li,LI Li-mingBIAN Xiao-jie,ZHANG Sheng-qiang. Bioequivalence of donepezil capsule and tablet in human[J]. Acta pharmaceutica Sinica, 2003, 38(5): 392-394
Authors:HAO Xin-yu  DING Li  LI Li-mingBIAN Xiao-jie  ZHANG Sheng-qiang
Affiliation:Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Abstract:AIM: To develop an HPLC-MS assay for determination of donepezil in human plasma and to investigate the pharmacokinetics and bioequivalence of donepezil capsule in healthy volunteers. METHODS: A randomized crossover design was performed in 20 healthy volunteers. In the two study periods, a single 5 mg dose of either capsule or tablet was administered to each volunteer. After spiked with the internal standard (phenoprolamine) and treated with saturated sodium bicarbonate, plasma was extracted with ethyl acetate and separated with a C18 reversed phase column. LC-ESIMS was used in the selected ion monitoring (SIM) mode with target ions at m/z 380 for donepezil and m/z 344 for phenoprolamine. The fragmentor voltage was 120 V. The main pharmacokinetic parameters of donepezil and the bioequivalence of its two preparations were calculated. RESULTS: The main pharmacokinetic parameters T1/2, Tmax and Cmax were (63 +/- 10) h, (3.3 +/- 0.4) h and (8.5 +/- 0.4) microgram.L-1 for the capsule; (57 +/- 9) h, (3.4 +/- 1.0) h and (8.1 +/- 1.0) microgram.L-1 for the tablet, respectively. The relative bioavailability of the donepezil capsule was 102% +/- 11%. CONCLUSION: The assay was shown to be sensitive, accurate and convenient. The two preparations of donepezil were bioequivalent.
Keywords:donepezil  pharmacokinetics  bioequivalence  HPLC MS
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《药学学报》浏览原始摘要信息
点击此处可从《药学学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号